Key facts
- It has raised $1.1M; the latest was Later Stage VC ($1.1M) in Jun 2025.
- Notable investors include National Library of Medicine.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for DeepRx
- ·The full record, as it builds
Funding rounds
No funding rounds for DeepRx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DeepRx
Developer of an AI-based intelligent platform intended to provide anticancer drugs. The company's platform offers chemotherapies, molecularly targeted anticancer drugs and immune therapies to exploit individual tumors, enabling patients to get effective drugs during the course of the disease.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2019
- Website
- deeprx.ai/
- Ownership
- Privately Held (backing)
DeepRx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DeepRx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DeepRx in its N-PORT filings yet. We sweep new filings monthly.